Approximately 70% of patients have hormone receptor-positive (HR+) and HER2-negative breast cancer cells; 15–20% have HER2-positive breast cancer; and 15% have triple-negative breast cancer (TNBC), tumors that lack all three standard molecular markers [5,9,10,11]. Here, ERBB2 is linked to breast cancer.